



For immediate release

04 May 2011

Zilico announces its plans to disseminate clinical trial results

Zilico has announced that, following completion of patient recruitment into its European multi-centre trial, it has identified a series of major international conferences at which results from this trial will be presented.

Mr John Tidy, Consultant Gynaecological Oncologist at the Royal Hallamshire Hospital Sheffield and founder of Zilico, has presented preliminary results at the recent meeting of the British Society of Colposcopy and Cervical Pathology in Liverpool on 30th March – 1st April 2011. Mr Tidy will also make an oral presentation of preliminary results at the EuroGIN meeting in Lisbon on 8th – 11th May 2011.

Zilico will have completed the analysis of the trial data by June 2011 and expects to present these data at the World Congress of Cervical Pathology and Colposcopy, which takes place in Rio on 4th – 7th July 2011, and at the International Meeting of the European Society for Gynaecological Oncology, which takes place in Milan on 10th – 14th September 2011.

In addition, Zilico will disseminate the trial results through its international network of Key Opinion Leaders (KOLs).

For more information please contact: Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: sameer.kothari@zilico.co.uk

Notes for editors:

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two product applications are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.

The European multi-centre trial is designed to demonstrate the performance of its portable diagnostic device within a cervical cancer screening programme. The device is positioned as an adjunct to colposcopy to help accurately identify sites for biopsy. The trial has been carried out at three centres with international reputations in colposcopy and cervical cancer. A total of over 400 women have now been recruited into the trial and Zilico expects to collect all the data and complete the analysis by June 2011. Zilico will use the data from this trial to obtain a CE Mark for the use of the device as an adjunct to colposcopy and expects to launch the product by the end of 2011.